Evidence map›Paper›PMID 41252050›Full record

ArticleJournal of gastrointestinal cancer2025

From Detection to Delay: Real-World Gaps in Post-Cologuard

Muhammad Ali Ibrahim Kazi, Imran Qureshi, Akshay Sharma, Nirav Agrawal, Mahnoor Sarfraz, Barry Meisenberg, Sanmeet Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad Ali Ibrahim KaziAnne Arundel Medical Center, Annapolis, MD, USA.
Imran QureshiRutgers New Jersey Medical School, Newark, NJ, USA. iaq5@njms.rutgers.edu.
Akshay SharmaAnne Arundel Medical Center, Annapolis, MD, USA. asharma@luminishealth.org.
Nirav AgrawalAnne Arundel Medical Center, Annapolis, MD, USA. nagrawal@luminishealth.org.
Mahnoor SarfrazAga Khan University, Karachi, Pakistan.
Barry MeisenbergAnne Arundel Medical Center, Annapolis, MD, USA.
Sanmeet SinghAnne Arundel Medical Center, Annapolis, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer remains a leading cause of cancer deaths, highlighting the need for early detection. Cologuard

methodsWe conducted a retrospective cohort study using the TriNetX database, a global federated real-world data platform, to analyze patients aged ≥ 18 years who tested positive on Cologuard. The primary outcome was whether patients underwent an endoscopic procedure (colonoscopy) within 12 months of a positive result. The secondary outcome was the diagnoses made during follow-up colonoscopy, including malignant neoplasms (colorectal cancer) and benign neoplasms (polyps).

resultsA total of 3,916 patients underwent Cologuard

conclusionThe study found poor follow-up adherence, with only 44% completing colonoscopy and a high false positive rate with just 38.5% of positive Cologuard

Indexed as

ColonoscopyColorectal NeoplasmsEarly Detection of CancerPatient ComplianceAgedBiomarkers, TumorDelayed DiagnosisFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesBiomarkers, TumorCancer screeningCare navigationCologuardColonoscopy adherenceColorectal cancer

Identifiers

PMID41252050
PMCPMC12722462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.